The delivery of nanovaccines containing cytosine-guanine oligodeoxynucleotides, STAT3 siRNA, and tumor-specific antigens to DCs significantly enhanced the CD8+ T cell responses and inhibited tumor growth [85]. This evidence concerns the gene CD8A and neoplasm.